Aurinia Pharma rises on exploring strategic alternatives

Aurinia Pharmaceuticals

30/06/2023 11:02

** U.S.-listed shares of drugmaker Aurinia Pharmaceuticals
 AUPH.O  gain 17% to $10.72 premarket    
    ** Co says its board has initiated an exploration of
strategic alternatives
    ** As part of the process, board to consider a range of
options for the co that can include potential sale, merger or
other strategic transaction - AUPH
    ** Adds that it has not set timetable for completion of this
process, and does not plan to share further developments unless
disclosure is appropriate or necessary 
    ** Co currently has one commercial product, Lupkynis, which
is approved by the U.S. FDA for treating a type of kidney
disease in adults 
    ** AUPH shares have more than doubled this year, as of last
close 

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))